Exact Mass: 703.5515607999998
Exact Mass Matches: 703.5515607999998
Found 500 metabolites which its exact mass value is equals to given mass value 703.5515607999998,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PE(P-18:0/16:0)
C39H78NO7P (703.5515607999998)
PE(P-18:0/16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/16:0), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of palmitic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/16:0), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of palmitic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(14:0/16:1(9Z))
PC(14:0/16:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:0/16:1(9Z)), in particular, consists of one chain of myristic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. The myristic acid moiety is derived from nutmeg and butter, while the palmitoleic acid moiety is derived from animal fats and vegetable oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(14:1(9Z)/16:0)
PC(14:1(9Z)/16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:1(9Z)/16:0), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The myristoleic acid moiety is derived from milk fats, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PC(15:0/P-16:0)
C39H78NO7P (703.5515607999998)
PC(15:0/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(15:0/P-16:0), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(15:0/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(15:0/P-16:0), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(16:0/14:1(9Z))
PC(16:0/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:0/14:1(9Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(16:0/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:0/14:1(9Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(16:1(9Z)/14:0)
PC(16:1(9Z)/14:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(16:1(9Z)/14:0), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of myristic acid at the C-2 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils, while the myristic acid moiety is derived from nutmeg and butter. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.
PE(15:0/18:1(11Z))
PE(15:0/18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(15:0/18:1(11Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the vaccenic acid moiety is derived from butter fat and animal fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. PE(15:0/18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(15:0/18:1(11Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the vaccenic acid moiety is derived from butter fat and animal fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(15:0/18:1(9Z))
PE(15:0/18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(15:0/18:1(9Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of oleic acid at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. PE(15:0/18:1(9Z)) is a phosphatidylethanolamine. It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 atoms. PE(15:0/18:1(9Z)), in particular, consists of one pentadecanoyl chain to the C-1 atom, and one 9Z-octadecenoyl to the C-2 atom. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS.
PE(16:0/P-18:0)
C39H78NO7P (703.5515607999998)
PE(16:0/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(16:0/P-18:0), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(16:0/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(16:0/P-18:0), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(18:0/P-16:0)
C39H78NO7P (703.5515607999998)
PE(18:0/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:0/P-16:0), in particular, consists of one chain of stearic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(18:1(11Z)/15:0)
PE(18:1(11Z)/15:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:1(11Z)/15:0), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS.
PE(18:1(9Z)/15:0)
PE(18:1(9Z)/15:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:1(9Z)/15:0), in particular, consists of one chain of oleic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. PE(18:1(9Z)/15:0) is a phosphatidylethanolamine. It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 atoms. PE(18:1(9Z)/15:0), in particular, consists of one 9Z-octadecenoyl chain to the C-1 atom, and one pentadecanoyl to the C-2 atom. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS.
PE(O-16:0/18:1(9Z))
C39H78NO7P (703.5515607999998)
2-(9Z-octadecanoyl)-1-hexadecyl-sn-glycero-3-phosphoethanolamine is an ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. 2-(9Z-octadecanoyl)-1-hexadecyl-sn-glycero-3-phosphoethanolamine is an ether lipid. Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage.
PC(P-16:0/15:0)
C39H78NO7P (703.5515607999998)
PC(P-16:0/15:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/15:0), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-16:0/15:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/15:0), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-16:0/18:0)
C39H78NO7P (703.5515607999998)
PE(P-16:0/18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/18:0), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of stearic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the stearic acid moiety is derived from animal fats, coco butter and sesame oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-16:0/18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/18:0), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of stearic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the stearic acid moiety is derived from animal fats, coco butter and sesame oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE-NMe(16:0/16:1(9Z))
PE-NMe(16:0/16:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(16:0/16:1(9Z)), in particular, consists of one hexadecanoyl chain to the C-1 atom, and one 9Z-hexadecenoyl to the C-2 atom. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE-NMe(14:0/18:1(9Z))
PE-NMe(14:0/18:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:0/18:1(9Z)), in particular, consists of one tetradecanoyl chain to the C-1 atom, and one 9Z-octadecenoyl to the C-2 atom. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE-NMe(14:0/18:1(11Z))
PE-NMe(14:0/18:1(11Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:0/18:1(11Z)), in particular, consists of one tetradecanoyl chain to the C-1 atom, and one 11Z-octadecenoyl to the C-2 atom. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE-NMe(14:1(9Z)/18:0)
PE-NMe(14:1(9Z)/18:0) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:1(9Z)/18:0), in particular, consists of one 9Z-tetradecenoyl chain to the C-1 atom, and one octadecanoyl to the C-2 atom. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE-NMe(16:1(9Z)/16:0)
PE-NMe(16:1(9Z)/16:0) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(16:1(9Z)/16:0), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of palmitic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe(18:0/14:1(9Z))
PE-NMe(18:0/14:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:0/14:1(9Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe(18:1(11Z)/14:0)
PE-NMe(18:1(11Z)/14:0) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:1(11Z)/14:0), in particular, consists of one chain of cis-vaccenic acid at the C-1 position and one chain of myristic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe(18:1(9Z)/14:0)
PE-NMe(18:1(9Z)/14:0) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:1(9Z)/14:0), in particular, consists of one chain of oleic acid at the C-1 position and one chain of myristic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
PE-NMe2(15:0/16:1(9Z))
PE-NMe2(15:0/16:1(9Z)) is a dimethylphosphatidylethanolamine. It is a glycerophospholipid, and is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Dimethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions.PE-NMe2(15:0/16:1(9Z)), in particular, consists of one pentadecanoyl chain to the C-1 atom, and one 9Z-hexadecenoyl to the C-2 atom. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE-NMe2(16:1(9Z)/15:0)
PE-NMe2(16:1(9Z)/15:0) is a dimethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Dimethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe2(16:1(9Z)/15:0), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.
10E-heptadecenoic acid
Phosphatidylethanolamine alkyl 16:0-18:1
C39H78NO7P (703.5515607999998)
Phosphatidylethanolamine alkenyl 18:0-16:0
C39H78NO7P (703.5515607999998)
PC 30:1
Found in mouse lung; TwoDicalId=150; MgfFile=160901_Lung_AA_Neg_17; MgfId=678 Found in mouse muscle; TwoDicalId=461; MgfFile=160824_Muscle_normal_Neg_01; MgfId=657
(2-aminoethoxy)[2-(hexadecanoyloxy)-3-[octadec-1-en-1-yloxy]propoxy]phosphinic acid
C39H78NO7P (703.5515607999998)
(2-{[2-[hexadec-9-enoyloxy]-3-(tetradecanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
PC(14:0/16:1)[U]
PE(O-16:0/18:1)
C39H78NO7P (703.5515607999998)
Lecithin
C39H78NO7P (703.5515607999998)
PE(34:0)
C39H78NO7P (703.5515607999998)
PC(O-16:0/15:1(9Z))
C39H78NO7P (703.5515607999998)
PC(P-18:0/13:0)
C39H78NO7P (703.5515607999998)
PE(O-20:0/14:1(9Z))
C39H78NO7P (703.5515607999998)
PE(O-18:0/16:1(9Z))
C39H78NO7P (703.5515607999998)
PE(P-20:0/14:0)
C39H78NO7P (703.5515607999998)
1-O-(alpha-D-galactopyranosyl)-N-tetracosanyl-2-aminononane-1,3,4-triol
A glycophytoceramide comprising (2S,3S,4R)-2-aminononane-1,3,4-triol having an alpha-D-galctopyranosyl residue at the O-1 position and an tetracosanoyl group attached to the nitrogen.
PC O-31:1
C39H78NO7P (703.5515607999998)
PE O-34:1
C39H78NO7P (703.5515607999998)
3,5,8-Trioxa-4-phosphahexacos-17-en-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[(1-oxododecyl)oxy]methyl]-, inner salt, 4-oxide, [R-(Z)]-
[2-[(Z)-hexadec-9-enoyl]oxy-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
N-[2-[[[[(2S,3R)-2-(Hexadecanoylamino)-3-hydroxy-4-octadecenyl]oxy]hydroxyphosphinyl]oxy]ethyl]trimethylaminium
C39H80N2O6P+ (703.5753690000001)
Phosphatidylethanolamine (1-palmitoyl, 2-cis-9,10-methylene hexadecanoyl)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[8-(2-hexylcyclopropyl)octanoyloxy]propyl] hexadecanoate
2-[[(2S,3R)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyoctadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
N-hexadecanoyl-1-O-beta-D-glucosyl-4-hydroxy-15-methylhexadecasphinganine
1-(1Z-octadecenyl)-sn-glycero-3-phospho-(N-palmitoyl)ethanolamine
C39H78NO7P (703.5515607999998)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(octadecanoylamino)hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E,2S,3R)-2-(heptadecanoylamino)-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E,2S,3R)-2-(heptadecanoylamino)-3-hydroxy-15-methylhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-5-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hexadecanoyloxypropyl] (Z)-heptadec-10-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] icosanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (Z)-octadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] hexadecanoate
C39H78NO7P (703.5515607999998)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-tetratriacont-23-enoate
C39H78NO7P (703.5515607999998)
[2-[(Z)-docos-13-enoyl]oxy-3-nonoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
3-Hydroxy-2-(2-hydroxyicosanoylamino)icosane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxyhexadecanoylamino)tetracosane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxyoctadecanoylamino)docosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octacos-17-enoxy]propan-2-yl] hexanoate
C39H78NO7P (703.5515607999998)
3-Hydroxy-2-(2-hydroxypentadecanoylamino)pentacosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (Z)-hexacos-15-enoate
C39H78NO7P (703.5515607999998)
3-Hydroxy-2-(2-hydroxynonadecanoylamino)henicosane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxyheptadecanoylamino)tricosane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxydocosanoylamino)octadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxyhenicosanoylamino)nonadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxytricosanoylamino)heptadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxypentacosanoylamino)pentadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxytetracosanoylamino)hexadecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxytetradecanoylamino)hexacosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexacos-15-enoxy]propan-2-yl] octanoate
C39H78NO7P (703.5515607999998)
3-Hydroxy-2-(2-hydroxyhexacosanoylamino)tetradecane-1-sulfonic acid
[3-[(Z)-hexacos-15-enoxy]-2-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-heptanoyloxy-3-[(Z)-tetracos-13-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-octacos-17-enoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-docos-13-enoxy]-2-nonanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
1-Pentadecanoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine-d7
(4E,8E)-2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxyhexadeca-4,8-diene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] (Z)-nonadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] (Z)-heptadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-henicos-11-enoxy]propan-2-yl] tridecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] henicosanoate
C39H78NO7P (703.5515607999998)
(E)-3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]octadec-4-ene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxyicosane-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(4E,8E)-3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]docosa-4,8-diene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(4E,8E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]tetracosa-4,8-diene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] pentadecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetracos-13-enoxy]propan-2-yl] decanoate
C39H78NO7P (703.5515607999998)
(4E,8E,12E)-2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxyhexadeca-4,8,12-triene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(4E,8E)-2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxyicosa-4,8-diene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(E)-2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxyicos-4-ene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]amino]octadecane-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(4E,8E,12E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxyicosa-4,8,12-triene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonadecoxypropan-2-yl] (Z)-pentadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] heptadecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (Z)-docos-13-enoate
C39H78NO7P (703.5515607999998)
(E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]docos-4-ene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-icos-11-enoxy]propan-2-yl] tetradecanoate
C39H78NO7P (703.5515607999998)
(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]docosa-4,8,12-triene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]tetracos-4-ene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-henicosoxypropan-2-yl] (Z)-tridec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (Z)-tetracos-13-enoate
C39H78NO7P (703.5515607999998)
2-[[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]amino]-3-hydroxyhexadecane-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (Z)-henicos-11-enoate
C39H78NO7P (703.5515607999998)
(4E,8E,12E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]octadeca-4,8,12-triene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(E)-2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxyhexadec-4-ene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]tetracosa-4,8,12-triene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
(4E,8E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]octadeca-4,8-diene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-icosoxypropan-2-yl] (Z)-tetradec-9-enoate
C39H78NO7P (703.5515607999998)
(4E,8E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyhexacosa-4,8-diene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] nonadecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-docos-13-enoxy]propan-2-yl] dodecanoate
C39H78NO7P (703.5515607999998)
(4E,8E,12E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyhexacosa-4,8,12-triene-1-sulfonic acid
C42H73NO5S (703.5209167999999)
[3-[(Z)-heptadec-9-enoxy]-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-[(Z)-hexadec-9-enoyl]oxy-3-pentadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-hexadecanoyloxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-octadecanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-[(Z)-icos-11-enoyl]oxy-3-undecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-dodecoxy-2-[(Z)-nonadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-decanoyloxy-3-[(Z)-henicos-11-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-heptadecoxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-icos-11-enoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-decoxy-2-[(Z)-henicos-11-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-dodecanoyloxy-3-[(Z)-nonadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-[(Z)-octadec-9-enoyl]oxy-3-tridecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] hexadecanoate
C39H78NO7P (703.5515607999998)
2-[[(E)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[3-octanoyloxy-2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]oxy-3-hexanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-decanoyloxy-2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2,3-bis[[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
4-[3-dodecanoyloxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-hexadecanoyloxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[(Z)-hexadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
[2-[(Z)-heptadec-9-enoyl]oxy-3-tetradecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-hexadec-9-enoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[2-heptadecanoyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-hexadecoxy-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octadecoxypropan-2-yl] (Z)-hexadec-9-enoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (Z)-icos-11-enoate
C39H78NO7P (703.5515607999998)
[3-octadecoxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[3-[(Z)-octadec-9-enoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] octadecanoate
C39H78NO7P (703.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (Z)-octadec-9-enoate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(Z)-tridec-9-enoyl]oxypropyl] icosanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (Z)-heptadec-9-enoate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(Z)-pentadec-9-enoyl]oxypropyl] octadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (Z)-icos-11-enoate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(Z)-hexadec-9-enoyl]oxypropyl] heptadecanoate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] nonadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (Z)-henicos-11-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (Z)-docos-13-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (Z)-nonadec-9-enoate
[3-dodecanoyloxy-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (E)-octadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (Z)-octadec-4-enoate
C39H78NO7P (703.5515607999998)
[3-pentadecanoyloxy-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hexanoyloxy-2-[(Z)-tetracos-13-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-butanoyloxy-2-[(Z)-hexacos-15-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (Z)-hexacos-15-enoate
[2-[(Z)-nonadec-9-enoyl]oxy-3-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
O-[[[(2R,3S,4E)-2-(Palmitoylamino)-3-hydroxy-4-octadecenyl]oxy]phosphonyl]choline
C39H80N2O6P+ (703.5753690000001)
4-[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-[(11E,14E)-icosa-11,14-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-decanoyloxy-2-[(10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2S)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-icos-1-enoxy]propan-2-yl] tetradecanoate
C39H78NO7P (703.5515607999998)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(tetradecanoylamino)icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[3-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(10E,12E)-octadeca-10,12-dienoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(2S,3R)-2-[[(E)-hexadec-9-enoyl]amino]-3-hydroxyoctadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[2-hexadecanoyloxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2S)-3-[(E)-icos-1-enoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
4-[3-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-2-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(14E,16E)-docosa-14,16-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(E)-icos-11-enoyl]amino]tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[3-hexadecanoyloxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] hexadecanoate
C39H78NO7P (703.5515607999998)
4-[3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(pentadecanoylamino)nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[3-[(9E,11E,13E)-henicosa-9,11,13-trienoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(E,2S,3R)-2-(heptadecanoylamino)-3-hydroxyheptadec-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(nonadecanoylamino)pentadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[2-dodecanoyloxy-3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(icosanoylamino)tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2R,3S)-3-hydroxy-2-(tridecanoylamino)henicos-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[2-[(10E,12E)-octadeca-10,12-dienoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-heptadec-7-enoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxy-3-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(E,2R,3S)-2-(dodecanoylamino)-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[2-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(E)-icos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2S)-3-[(E)-octadec-1-enoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
2-[[(E,2R,3S)-2-(dodecanoylamino)-3-hydroxydocos-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[3-dodecanoyloxy-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-octadec-11-enoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(E)-hexadec-7-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E)-henicosa-9,11,13-trienoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-octadec-11-enoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxy-2-tridecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(14E,16E)-docosa-14,16-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-dodec-5-enoyl]oxy-2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(octadecanoylamino)hexadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] octadecanoate
C39H78NO7P (703.5515607999998)
2-[[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[3-[(E)-heptadec-7-enoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2,3-bis[[(4E,7E)-hexadeca-4,7-dienoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoyl]oxy-2-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(2S,3R)-2-[[(E)-heptadec-9-enoyl]amino]-3-hydroxyheptadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(pentadecanoylamino)nonadec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[3-[(E)-dec-4-enoyl]oxy-2-[(13E,16E,19E)-docosa-13,16,19-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-dec-4-enoyl]oxy-3-[(13E,16E,19E)-docosa-13,16,19-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(icosanoylamino)tetradec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(E)-octadec-9-enoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[2-[(E)-dodec-5-enoyl]oxy-3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2R,3S)-3-hydroxy-2-(tridecanoylamino)henicos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[2-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(nonadecanoylamino)pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
4-[2-decanoyloxy-3-[(10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(E)-hexadec-7-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(10E,13E,16E)-nonadeca-10,13,16-trienoyl]oxy-2-[(E)-tridec-8-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E,15E)-henicosa-9,11,13,15-tetraenoyl]oxy-3-undecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(E)-icos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-3-[(E)-hexadec-1-enoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C39H78NO7P (703.5515607999998)
4-[2-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[(11E,14E)-icosa-11,14-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-2-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-(tetradecanoylamino)icos-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(tetradecanoylamino)icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]icosoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]nonadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]pentadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(pentadecanoylamino)nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxyoctadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(icosanoylamino)tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(dodecanoylamino)-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(octadecanoylamino)hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-dodec-5-enoyl]amino]-3-hydroxydocosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(heptadecanoylamino)-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]henicosoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(tridecanoylamino)henicos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(nonadecanoylamino)pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(decanoylamino)-3-hydroxytetracos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(docosanoylamino)-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(8E,12E)-3,4-dihydroxy-2-(pentadecanoylamino)octadeca-8,12-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C38H76N2O7P+ (703.5389855999999)
2-[[2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxytridecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyoctadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]decoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)nonacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]henicosoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(tricosanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-docos-13-enoyl]amino]-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(hexanoylamino)-3-hydroxyoctacos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxyoctoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(heptanoylamino)-3-hydroxyheptacos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)hentriacont-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(butanoylamino)-3-hydroxytriacont-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(pentacosanoylamino)non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-3,4-dihydroxy-2-[[(Z)-pentadec-9-enoyl]amino]octadec-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C38H76N2O7P+ (703.5389855999999)
2-[[(E)-2-acetamido-3-hydroxydotriacont-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(henicosanoylamino)-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(nonanoylamino)pentacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxyheptadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[[(E)-2-(hexacosanoylamino)-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)hexacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(tetracosanoylamino)dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-(undecanoylamino)tricos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C39H80N2O6P+ (703.5753690000001)
1-(1Z-octadecenyl)-2-hexadecanoyl-sn-glycero-3-phosphoethanolamine
C39H78NO7P (703.5515607999998)
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z)-octadecenyl and hexadecanoyl respectively.
1-Pentadecanoyl-2-(1-enyl-palmitoyl)-sn-glycero-3-phosphocholine
C39H78NO7P (703.5515607999998)
MePC(30:1)
C39H78NO7P (703.5515607999998)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(33:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
dMePE(32:1)
C39H78NO7P (703.5515607999998)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(32:1)
C38H73NO10 (703.5234197999999)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(2s,3r,4s,5r,6s)-6-{[(2s,3r)-2-[(1,2-dihydroxytetradecylidene)amino]-3-hydroxyoctadecyl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
C38H73NO10 (703.5234197999999)
6-({2-[(1,2-dihydroxytetradecylidene)amino]-3-hydroxyoctadecyl}oxy)-3,4,5-trihydroxyoxane-2-carboxylic acid
C38H73NO10 (703.5234197999999)